Caris Life Sciences (CAI) Expands AI Insights Portfolio With Signature to Predict Ovarian Cancer Platinum Resistance

Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best NASDAQ stocks under $30 to buy. On March 16, Caris Life Sciences expanded its Caris AI Insights portfolio with a new AI signature designed to predict early platinum resistance in patients with high-grade serous ovarian cancer/HGSOC. This tool uses the company’s proprietary CodeAI platform to analyze Whole Exome Sequencing/WES, Whole Transcriptome Sequencing/WTS, and clinical data.

The signature aims to provide clinicians with molecular foresight into how long a patient might benefit from standard platinum-based chemotherapy before disease progression. HGSOC is an aggressive cancer often diagnosed at advanced stages, with ~20% to 30% of patients experiencing resistance within 6 months of their first treatment. By generating a risk score and classifying patients as platinum-sensitive or platinum-resistant, this technology helps doctors identify those who may need to transition quickly to alternative therapies.

This is particularly significant following recent FDA approvals for new combination treatments specifically targeting platinum-resistant cases. The ovarian cancer AI signature is currently available upon request via the Caris Molecular Tumor Board Report when using the company’s MI Cancer Seek tissue-based test. This test, which received FDA approval in late 2024, is the first of its kind to offer simultaneous WES and WTS-based molecular profiling.

Caris Life Sciences Inc. (NASDAQ:CAI) is a biotech company that provides molecular profiling services and develops & commercializes healthcare solutions using molecular information and AI/ML algorithms.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.